治疗前中性粒细胞与淋巴细胞比值(NLR)预测可手术头颈癌的治疗毒性和不耐受:一项双向性队列研究
本研究为双向性队列研究,纳入两家学术医院456例可手术、II-IV期、HPV阴性头颈癌患者,评估治疗前NLR与短期治疗结局的关联。194例发生治疗相关毒性(≥3级不良事件),200例出现治疗不耐受(因耐受性差停药或延迟)。治疗前高NLR与毒性风险升高(OR 1.04;95%CI:1.00-1.09)和不耐受风险升高(OR 1.06;95%CI:1.01-1.12)显著相关;NLR<2.5者经多因素校正后毒性和不耐受的比值比均显著降低。
要点
- 治疗前高NLR与可手术头颈癌患者治疗毒性风险升高相关(OR 1.04;95%CI:1.00-1.09)。
- 治疗前高NLR与治疗不耐受风险升高相关(OR 1.06;95%CI:1.01-1.12)。
- NLR<2.5者经多因素校正后毒性和不耐受的比值比均显著降低。
核心结论
- 低治疗前NLR与可手术头颈癌患者治疗毒性降低和不耐受率降低相关。
研究设计与样本
- 双向性队列研究,纳入两家学术医院456例可手术、II-IV期、HPV阴性头颈癌患者,采用多因素logistic回归分析治疗前NLR与短期治疗结局的关联。
主要发现
- 456例中194例发生治疗相关毒性(定义为≥3级不良事件),200例出现治疗不耐受(定义为因耐受性差停药或延迟)。
- 治疗前高NLR与毒性风险升高显著相关(OR 1.04;95%CI:1.00-1.09),与不耐受风险升高显著相关(OR 1.06;95%CI:1.01-1.12)。
- 经多因素混杂校正后,NLR<2.5者发生毒性的比值比显著降低(OR 0.50;95%CI:0.26-0.96),发生不耐受的比值比显著降低(OR 0.57;95%CI:0.33-0.99)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pretreatment neutrophil to lymphocyte ratio (NLR) is a negative prognostic marker for survival in head and neck cancer (HNC). Its association with treatment toxicity and intolerance in patients undergoing curative-intent surgery is unknown. METHODS: Ambispective study of patients with operable stage II-IV, HPV-negative HNC treated at two academic hospitals. Multiple logistic regression was performed to evaluate the association between pretreatment NLR and short-term treatment outcomes including treatment toxicity and intolerance. RESULTS: Among 456 patients, 194 experienced treatment-related toxicity, defined as grade ≥ 3 adverse events, and 200 exhibited treatment intolerance, defined as treatment discontinuation or delay due to poor tolerance. High pretreatment NLR was significantly associated with an increased risk of toxicity (OR 1.04; 95% CI: 1.00-1.09) and intolerance (OR 1.06; 95% CI: 1.01-1.12). Patients with an NLR < 2.5 had significantly lower odds of experiencing toxicity (OR 0.50; 95% CI: 0.26-0.96) and intolerance (OR 0.57; 95% CI: 0.33-0.99) after adjusting for multiple confounders. CONCLUSIONS: Low pretreatment NLR was associated with reduced treatment toxicity and lower rates of intolerance in patients undergoing curative-intent surgery for HNC.
引用
- Chowdhury R, Botros K, Richardson K, et al. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) Predicts Treatment Toxicity and Intolerance in Operable Head and Neck Cancer: An Ambispective Cohort Study. Head Neck. 2025. PMID: 40491270. doi:10.1002/hed.28212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。